GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint
GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint
癌症治疗药物组合未能达到主要终点后,GlycoMimetics股价暴跌
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册